Who makes AN2728 Ointment, 0.5%?

AN2728 Ointment, 0.5% is developed by Pfizer.

What development phase is AN2728 Ointment, 0.5% in?

AN2728 Ointment, 0.5% is in Phase 1.

Last reviewed 2026-05-15 · How we verify

AN2728 Ointment, 0.5%

Pfizer · Phase 1 active Small molecule

At a glance

Generic name	AN2728 Ointment, 0.5%
Sponsor	Pfizer
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test (PHASE1)
Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis (PHASE2)
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AN2728 Ointment, 0.5% CI brief — competitive landscape report
AN2728 Ointment, 0.5% updates RSS · CI watch RSS
Pfizer portfolio CI